study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,intervention,control,outcome,duration_weeks,population
yohimbine_2010_1,2010,RCT,MD,-2.335,-2.495,-2.176,62,109,some,10.4271/j.clin_j_am_soc_nephrol.2010.2589,clin_j_am_soc_nephrol,Yohimbine supplement,Placebo,eGFR (mL/min/1.73m²),6,Patients with CKD
yohimbine_2011_2,2011,RCT,MD,-1.216,-1.626,-0.807,75,85,some,10.2493/j.am_j_cardiol.2011.9914,am_j_cardiol,Yohimbine supplement,Placebo,Proteinuria,6,Elderly adults
yohimbine_2010_3,2010,RCT,MD,-2.092,-2.293,-1.891,84,58,low,10.2009/j.am_j_cardiol.2010.3476,am_j_cardiol,Yohimbine supplement,Placebo,eGFR (mL/min/1.73m²),4,Elderly adults
yohimbine_2023_4,2023,RCT,MD,0.031,-0.335,0.397,91,78,high,10.4860/j.clin_j_am_soc_nephrol.2023.8803,clin_j_am_soc_nephrol,Yohimbine supplement,Placebo,BUN (mg/dL),4,Athletes
